The effect of liver test abnormalities on the prognosis of covid-19.

CONCLUSIONS: ALT-AST elevation and AST/ALT ratio>1 was associated with more severe course and increased mortality in COVID-19. PMID: 32920162 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research

Related Links:

At the end of January 2020, the World Health Organization (WHO) declared the SARS-Cov-2 (or Coronavirus 19 [COVID-19]) infection a global health emergency [1]. The virus, belonging to the β-Coronaviruses, spreads mainly through the respiratory tract from person to person, using the transmembrane serine protease 2 (TMPRSS2) [2] for S spike-protein priming and the angiotensin-converting-enzyme 2 (ACE2) receptors, receptors sited not only in the pulmonary epithelium but also in others districts such as in the renal and gastrointestinal ones [3].
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
SARS-CoV-2 is transmitted by droplets and likely aerosols. The median incubation period is about 5-6 days (range 1-14 days)1 and the median age at confirmed infection in Germany is 49 years. Typical symptoms include fever, cough, anosmia, ageusia, and pneumonia. The mortality rate of COVID-19 is higher among elderly and among ethnicities other than Caucasians. Furthermore, a markedly higher mortality rate has been observed for several comorbidities including obesity class II (BMI 35 •0-39•9 kg/m2) and III (BMI 40•0+ kg/m2), uncontrolled diabetes mellitus, malignancies in the previous year, severely reduced g...
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research
Bandar Al-Judaibi, Reem Almaghrabi, Mohammed Alghamdi, Waleed K Al-Hamoudi, Mohammed AlQahtani, Faisal Abaalkhail, Mohammed Shagrani, Faisal M SanaiSaudi Journal of Gastroenterology 2020 26(5):233-239 The World Health Organization (WHO), on March 11th 2020, upgraded the status of the novel coronavirus disease (COVID-19) from epidemic to pandemic. Over two million individuals have been infected with SARS-CoV-2, the virus causing COVID-19, and as of April, 14th 2020, there were over 5000 confirmed cases in Saudi Arabia (SA). Many countries, including SA, have imposed major restrictions on travel, and everyday life, and the ...
Source: The Saudi Journal of Gastroenterology - Category: Gastroenterology Authors: Source Type: research
The microbiota-gut-liver-lung axis plays a bidirectional role in the pathophysiology of a number of infectious diseases. During the course of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and 2 (SARS-CoV-2) infection, this pathway is unbalanced due to intestinal involvement and systemic inflammatory response. Moreover, there is convincing preliminary evidence linking microbiota-gut-liver axis perturbations, proinflammatory status, and endothelial damage in noncommunicable preventable diseases with coronavirus disease 2019 (Covid-19) severity.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Source Type: research
In December 2019 an outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously 2019-nCoV) started in Wuhan, China, and has since become a global threat to human health1. In patients affected with this virus, 14 –53% cases reported abnormal levels of alanine aminotransferase and aspartate aminotransferase (AST) during disease progression1. Autoimmune hepatitis (AIH) is a rare autoimmune liver disease that is still poorly understood2. The cornerstone of treatment is the use of immunosuppressive drugs inclu ding azathioprine and corticosteroids.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
AbstractObjectivesThe OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.Trial designThe OVID study is conducted as a multicentre open-label superiority randomised controlled trial.ParticipantsInclusion Criteria1. Signed patient informed consent after being fully informed about the study ’s background.2. Patients aged 50 years or older with a positive test for SARS-...
Source: Trials - Category: Research Source Type: clinical trials
Semin Liver Dis 2020; 40: 321-330 DOI: 10.1055/s-0040-1715108Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the ...
Source: Seminars in Liver Disease - Category: Gastroenterology Authors: Tags: Review Article Source Type: research
The coronavirus disease-2019 (COVID-19) has become a global pandemic affecting over 192 countries [1]. It is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which enters cells via interactions with angiotensin converting enzyme II (ACE2) receptors that line the respiratory tract, esophagus, ileum and colon, thereby providing a potential means for fecal-oral transmission [2]. Concurrent gastrointestinal (GI) complaints have been reported in up to 61% of COVID-19 patients [3], and early reports from Asian populations suggested that hospitalized COVID-19 patients with concurrent GI symptoms require...
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research
Background: The pandemic of coronavirus disease 2019 (COVID-19) has diverted resources from healthcare services for patients with chronic medical illness such as cancer. COVID-19 also causes organ dysfunction, complicating cancer treatment. In most countries with an outbreak of COVID-19, modifications of cancer management have been adopted to accommodate the crisis and minimize the exposure of cancer patients to the infection. In countries where COVID-19 numbers are subsiding, medical teams should also be prepared to resume normal practices gradually. Here, we aim to review the literature on the impact of COVID-19 on patie...
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
Since December 2019, a novel coronavirus named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) was identified as the causative agent of a respiratory syndrome named COVID-19 [1]. During the following months, the virus rapidly spread around the world, until the World Health Organization (WHO) defined COVID-19 as a pandemic on 11 March 2020. Lombardy region was severely hit by COVID-19 since February 2020, posing serious challenges to healthcare system due to an extremely high number of simultaneous cases.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research
More News: Cancer & Oncology | COVID-19 | Gastroenterology | Hematology | Intensive Care | Liver | Liver Disease | SARS | Statistics | Study | Urology & Nephrology